

Ref: FOI/GS/ID 5593

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

27 November 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cutaneous Squamous Cell Carcinoma.

You asked:

Question 1 – How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?

Question 2 – How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?

*Question 3 – Of these how many are not candidates for Curative surgery or Curative Radiation? **

Question 4 – In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following:

Question 5 – Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)?

If yes, please state which?

**Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely*

CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection

** Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:*

CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition

Clinical judgement that tumour might not respond to RT

Factors / conditions contradicting for RT

Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does

*** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide*

Trust response:

Due to the very small number of cases, less than 5, and in order to protect patient confidentiality the Trust has therefore decided that such requests will normally be refused using the limitations available under Section 10 and Section 11 of the Data Protection Act 1998.

5. No